We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Direct and Indirect Mitigation Strategies for Microplastic and Nanoplastic Exposure: A Conceptual Framework for Combination Therapeutic Development
Summary
Tiny plastic particles from our environment may get into our bodies and contribute to inflammation, stress on cells, immune problems, and even brain and heart issues over time. This paper doesn't test new treatments—instead, it proposes a game plan for future research: combining strategies that reduce how much plastic gets into our tissues with treatments that calm the harmful effects those particles might cause. It's an early-stage roadmap for scientists, not a proven fix, but it highlights why tackling microplastic exposure may eventually require a two-pronged medical approach.
Microplastics and nanoplastics (MPs/NPs) are emerging environmental exposure agents with potential relevance to inflammation, oxidative stress, immune dysregulation, endothelial dysfunction, neuroinflammation, and long-term healthspan. Therapeutic development in this area may require both direct mitigation strategies, aimed at reducing particle burden or interaction with tissues, and indirect mitigation strategies, aimed at modulating downstream biological consequences. This technical note outlines a conceptual framework for direct and indirect MP/NP mitigation, including possible combination approaches with existing anti-inflammatory, metabolic, neuroprotective, cardiovascular, and immunomodulatory therapies. The purpose is not to claim demonstrated clinical efficacy, but to define a translational strategy for future testing, partnership development, and resilience-focused therapeutic design.